Mach7 Technologies Ltd
ASX:M7T

Watchlist Manager
Mach7 Technologies Ltd Logo
Mach7 Technologies Ltd
ASX:M7T
Watchlist
Price: 0.505 AUD 2.02%
Market Cap: 118.7m AUD

Mach7 Technologies Ltd
Investor Relations

Mach7 Technologies Ltd. provides medical imaging software and services for healthcare institutions. The company is headquartered in Melbourne, Victoria and currently employs 90 full-time employees. The company went IPO on 2005-11-30. The principal activities of the Company include the provision of enterprise imaging data sharing, storage and interoperability for healthcare enterprises globally. The firm operates through two segments: sale of software and rendering of professional services. The sale of software segment engaged in selling software licenses. The provision of the software license is a distinct performance obligation as the customer can derive substantial benefits from the license on its own when the license is delivered and installed. Healthcare enterprises globally segment engaged in providing professional services, such as implementation, training and annual support services. The firm provides various solutions, including Enterprise Diagnostic Viewing, Enterprise Data Management and Enterprise PACS.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q1 2026
Call Date
Oct 30, 2025
AI Summary
Q1 2026

Reset Quarter: Q1 FY26 was described as a reset, with tough decisions made to strengthen Mach7 for long-term profitability and operational excellence.

Stable Recurring Revenue: Annual recurring revenue run rate rose slightly to $23.5 million, emphasizing the durability of Mach7's subscription and maintenance business.

Sales Growth: Sales orders grew 17% year-on-year to $2.6 million, reflecting improved customer engagement despite broader sales team changes.

Cash Flow Timing Impact: Operating cash flow decreased due to delayed customer renewals, not lower demand. Adjusted for timing, cash flow would have met expectations.

Cost Discipline: Staff costs were reduced by 18% year-on-year, and total payments fell 16%, as part of ongoing efficiency efforts.

Strong Balance Sheet: Mach7 ended the quarter with $18.9 million in cash and zero debt.

VA Contract Progress: Achieved initial go-live for the major U.S. Veterans Health Administration National Teleradiology Program contract; full rollout to more departments is underway.

Strategic Focus: The company is not currently pursuing acquisitions or a U.S. listing, maintains a cautious approach to cash use, and paused its share buyback pending a strategic review.

Key Financials
Annual Recurring Revenue Run Rate
$23.5 million
Contracted Annual Recurring Revenue (CARR)
$29.6 million
Sales Orders
$2.6 million
Receipts from Customers
$4.6 million
Total Payments
$8.3 million
Admin and Corporate Costs
$2 million
Cash Balance
$18.9 million
Debt
Zero
Earnings Call Recording
Other Earnings Calls

Management

Mr. Michael Lampron
CEO, MD & Director
No Bio Available
Ms. Dyan O'Herne
Chief Financial Officer
No Bio Available
Mr. David Madaffri
Chief Operating Officer
No Bio Available
Francoise Dixon
Head of Investor Relations
No Bio Available
Mr. Bob Tranchida
Vice President of Marketing
No Bio Available
Ms. Kelly Kimball
Vice President of People & Culture
No Bio Available
Mr. Anthony W. Panther A.C.I.S., AGIA, B.E., C.A., L.L.B., LL.B
Company Secretary
No Bio Available

Contacts

Address
VICTORIA
Melbourne
L 1 61 Spring Street
Contacts
+61392867500.0
www.mach7t.com